SCIENTURE HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations
SCIENTURE HOLDINGS, INC. (SCNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations of 0 shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-22.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations · last filed 2024-04-22
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2023-12-31 was 0.00 shares.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2023-09-30 was 0.00 shares.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2023-06-30 was 0.00 shares.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2023-03-31 was 0.00 shares.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2023 was 0.00 shares.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2020 was 33.34K shares, a 1100.00% increase from fiscal 2019.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2019 was 2.78K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 12 month |
|---|---|---|---|---|
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-22 | 0.00 shares derived: sum of 2 quarters · filed 2024-04-22 | 0.00 shares derived: sum of 3 quarters · filed 2024-04-22 | 0.00 shares 10-K · filed 2024-04-22 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-01-16 | 0.00 shares derived: sum of 2 quarters · filed 2024-01-16 | 0.00 shares 10-Q · filed 2024-01-16 | |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-18 | 0.00 shares 10-Q · filed 2023-08-18 | ||
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-15 | |||
| 2021-09-30 | 28.78K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-25 | 35.66K shares 10-Q · filed 2021-10-25 | ||
| 2021-06-30 | 6.88K shares 10-Q · filed 2021-07-26 | |||
| 2020-12-31 | 25.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | 25.00K shares derived: sum of 2 quarters · filed 2021-03-29 | 33.34K shares 10-K · filed 2021-03-29 | |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-26 | 8.34K shares 10-Q · filed 2020-10-26 | ||
| 2020-06-30 | 8.34K shares 10-Q · filed 2020-07-27 | |||
| 2019-12-31 | 2.78K shares 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |